FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:1649-1660 May 27, 1999 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The myelodysplastic syndromes are clonal hematologic disorders characterized clinically and morphologically by ineffective hematopoiesis. The natural history of these syndromes ranges from a chronic course that may span years to a rapid course of leukemic progression. Unfortunately, the nomenclature and classification systems used to describe these conditions are cumbersome and contentious. Nonetheless, myelodysplastic syndromes are viewed by most hematologists as encompassing stages of neoplastic hematopoiesis associated with cytopenias and as excluding nonneoplastic conditions. In general, myelodysplastic conditions are preleukemic disorders in which the neoplastic clone is established, but not all cases of myelodysplasia terminate in acute myeloid leukemia (AML). Here, . . . [Full Text of this Article]

The Hematopoietic Stem Cell and Its Neoplastic Transformation

History and Classification of Myelodysplasia

Pathogenesis, Pathophysiology, and Molecular Pathology

Diagnosis

Clinical Syndromes and Manifestations

The 5q– Syndrome

Hypoplastic Myelodysplasia

Childhood Myelodysplasia

Myelodysplasia with Bone Marrow Fibrosis

Therapy-Related Myelodysplasia

Treatment

Chemotherapy

Agents with Novel Mechanisms of Action

Immunotherapy

Hematopoietic Hormones and Cytokines

Stem-Cell Transplantation

Overall Approach to Treatment

Future Treatment

Source Information

From the Department of Medicine (M.L.H., D.W.G.) and the Program in Molecular Pharmacology and Therapeutics (D.W.G.), Memorial Sloan-Kettering Cancer Center, New York.

Address reprint requests to Dr. Golde at Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021, or at d-golde@ski.mskcc.org.

References

This article has been cited by other articles:

• Choi, C. W., Chung, Y. J., Slape, C., Aplan, P. D. (2008). Impaired differentiation and apoptosis of hematopoietic precursors in a mouse model of myelodysplastic syndrome. haematol 93: 1394-1397 [Abstract] [Full Text]  
• Jadersten, M., Malcovati, L., Dybedal, I., Giovanni Della Porta, M., Invernizzi, R., Montgomery, S. M., Pascutto, C., Porwit, A., Cazzola, M., Hellstrom-Lindberg, E. (2008). Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome. JCO 26: 3607-3613 [Abstract] [Full Text]  
• Wang, L., Fidler, C., Nadig, N., Giagounidis, A., Della Porta, M. G., Malcovati, L., Killick, S., Gattermann, N., Aul, C., Boultwood, J., Wainscoat, J. S. (2008). Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays. haematol 93: 994-1000 [Abstract] [Full Text]  
• Hamada, T., Matsuura, H., Oono, T., Morizane, S., Yamasaki, O., Asagoe, K., Yamamoto, T., Tsuji, K., Iwatsuki, K. (2008). Karyotypic Analysis of Bone Marrow Cells in Pyodermic Lesions Associated With Myelodysplastic Syndrome. Arch Dermatol 144: 643-648 [Abstract] [Full Text]  
• Watanabe-Okochi, N., Kitaura, J., Ono, R., Harada, H., Harada, Y., Komeno, Y., Nakajima, H., Nosaka, T., Inaba, T., Kitamura, T. (2008). AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 111: 4297-4308 [Abstract] [Full Text]  
• Kiladjian, J.-J., Visentin, G., Viey, E., Chevret, S., Eclache, V., Stirnemann, J., Bourhis, J. H., Chouaib, S., Fenaux, P., Caignard, A. (2008). Activation of cytotoxic T-cell receptor {gamma}{delta} T lymphocytes in response to specific stimulation in myelodysplastic syndromes. haematol 93: 381-389 [Abstract] [Full Text]  
• Gondek, L. P., Tiu, R., O'Keefe, C. L., Sekeres, M. A., Theil, K. S., Maciejewski, J. P. (2008). Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111: 1534-1542 [Abstract] [Full Text]  
• Haase, D., Germing, U., Schanz, J., Pfeilstocker, M., Nosslinger, T., Hildebrandt, B., Kundgen, A., Lubbert, M., Kunzmann, R., Giagounidis, A. A. N., Aul, C., Trumper, L., Krieger, O., Stauder, R., Muller, T. H., Wimazal, F., Valent, P., Fonatsch, C., Steidl, C. (2007). New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110: 4385-4395 [Abstract] [Full Text]  
• Nilsson, L., Eden, P., Olsson, E., Mansson, R., Astrand-Grundstrom, I., Strombeck, B., Theilgaard-Monch, K., Anderson, K., Hast, R., Hellstrom-Lindberg, E., Samuelsson, J., Bergh, G., Nerlov, C., Johansson, B., Sigvardsson, M., Borg, A., Jacobsen, S. E. W. (2007). The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. Blood 110: 3005-3014 [Abstract] [Full Text]  
• Jabbour, E., Kantarjian, H. M., Abruzzo, L. V., O'Brien, S., Garcia-Manero, G., Verstovsek, S., Shan, J., Rios, M. B., Cortes, J. (2007). Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 110: 2991-2995 [Abstract] [Full Text]  
• Pellagatti, A., Jadersten, M., Forsblom, A.-M., Cattan, H., Christensson, B., Emanuelsson, E. K., Merup, M., Nilsson, L., Samuelsson, J., Sander, B., Wainscoat, J. S., Boultwood, J., Hellstrom-Lindberg, E. (2007). Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc. Natl. Acad. Sci. USA 104: 11406-11411 [Abstract] [Full Text]  
• Aivado, M., Spentzos, D., Germing, U., Alterovitz, G., Meng, X.-Y., Grall, F., Giagounidis, A. A. N., Klement, G., Steidl, U., Otu, H. H., Czibere, A., Prall, W. C., Iking-Konert, C., Shayne, M., Ramoni, M. F., Gattermann, N., Haas, R., Mitsiades, C. S., Fung, E. T., Libermann, T. A. (2007). From the cover: Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc. Natl. Acad. Sci. USA 104: 1307-1312 [Abstract] [Full Text]  
• Navas, T. A., Mohindru, M., Estes, M., Ma, J. Y., Sokol, L., Pahanish, P., Parmar, S., Haghnazari, E., Zhou, L., Collins, R., Kerr, I., Nguyen, A. N., Xu, Y., Platanias, L. C., List, A. A., Higgins, L. S., Verma, A. (2006). Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 108: 4170-4177 [Abstract] [Full Text]  
• Pellagatti, A., Cazzola, M., Giagounidis, A. A. N., Malcovati, L., Porta, M. G. D., Killick, S., Campbell, L. J., Wang, L., Langford, C. F., Fidler, C., Oscier, D., Aul, C., Wainscoat, J. S., Boultwood, J. (2006). Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood 108: 337-345 [Abstract] [Full Text]  
• Nimer, S. D. (2006). Clinical Management of Myelodysplastic Syndromes With Interstitial Deletion of Chromosome 5q. JCO 24: 2576-2582 [Abstract] [Full Text]  
• Mihara, K., Chowdhury, M., Nakaju, N., Hidani, S., Ihara, A., Hyodo, H., Yasunaga, S., Takihara, Y., Kimura, A. (2006). Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Blood 107: 305-308 [Abstract] [Full Text]  
• Evan, P., Mettler, F. A. Jr. (2005). Radiation Workers at Higher Risk for Developing Myelodysplastic Syndrome. Am. J. Roentgenol. 184: 1967-1967 [Full Text]  
• Chan, E. M., Comer, E. M., Brown, F. C., Richkind, K. E., Holmes, M. L., Chong, B. H., Shiffman, R., Zhang, D.-E., Slovak, M. L., Willman, C. L., Noguchi, C. T., Li, Y., Heiber, D. J., Kwan, L., Chan, R. J., Vance, G. H., Ramsey, H. C., Hromas, R. A. (2005). AML1-FOG2 fusion protein in myelodysplasia. Blood 105: 4523-4526 [Abstract] [Full Text]  
• Ogata, K., Satoh, C., Tachibana, M., Hyodo, H., Tamura, H., Dan, K., Kimura, T., Sonoda, Y., Tsuji, T. (2005). Identification and Hematopoietic Potential of CD45- Clonal Cells with Very Immature Phenotype (CD45-CD34-CD38-Lin-) in Patients with Myelodysplastic Syndromes. Stem Cells 23: 619-630 [Abstract] [Full Text]  
• Houwerzijl, E. J., Blom, N. R., van der Want, J. J. L., Louwes, H., Esselink, M. T., Smit, J. W., Vellenga, E., de Wolf, J. Th. M. (2005). Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients. Blood 105: 3472-3479 [Abstract] [Full Text]  
• Wolfler, A., Erkeland, S. J., Bodner, C., Valkhof, M., Renner, W., Leitner, C., Olipitz, W., Pfeilstocker, M., Tinchon, C., Emberger, W., Linkesch, W., Touw, I. P., Sill, H. (2005). A functional single-nucleotide polymorphism of the G-CSF receptor gene predisposes individuals to high-risk myelodysplastic syndrome. Blood 105: 3731-3736 [Abstract] [Full Text]  
• Campioni, D., Secchiero, P., Corallini, F., Melloni, E., Capitani, S., Lanza, F., Zauli, G. (2005). Evidence for a Role of TNF-Related Apoptosis-Inducing Ligand (TRAIL) in the Anemia of Myelodysplastic Syndromes. Am. J. Pathol. 166: 557-563 [Abstract] [Full Text]  
• Tsimberidou, A.-M., Giles, F. J., Khouri, I., Bueso-Ramos, C., Pilat, S., Thomas, D. A., Cortes, J., Kurzrock, R. (2005). Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. Ann Oncol 16: 139-145 [Abstract] [Full Text]  
• Guralnik, J. M., Eisenstaedt, R. S., Ferrucci, L., Klein, H. G., Woodman, R. C. (2004). Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 104: 2263-2268 [Abstract] [Full Text]  
• Giannouli, S., Voulgarelis, M., Zintzaras, E., Tzioufas, A. G., Moutsopoulos, H. M. (2004). Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology (Oxford) 43: 626-632 [Abstract] [Full Text]  
• Malins, D. C., Anderson, K. M., Polissar, N. L., Ostrander, G. K., Knobbe, E. T., Green, V. M., Gilman, N. K., Spivak, J. L. (2004). Models of granulocyte DNA structure are highly predictive of myelodysplastic syndrome. Proc. Natl. Acad. Sci. USA 101: 5008-5011 [Abstract] [Full Text]  
• Kurzrock, R., Albitar, M., Cortes, J. E., Estey, E. H., Faderl, S. H., Garcia-Manero, G., Thomas, D. A., Giles, F. J., Ryback, M. E., Thibault, A., De Porre, P., Kantarjian, H. M. (2004). Phase II Study of R115777, a Farnesyl Transferase Inhibitor, in Myelodysplastic Syndrome. JCO 22: 1287-1292 [Abstract] [Full Text]  
• Ishiyama, K., Chuhjo, T., Wang, H., Yachie, A., Omine, M., Nakao, S. (2003). Polyclonal hematopoiesis maintained in patients with bone marrow failure harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood 102: 1211-1216 [Abstract] [Full Text]  
• Cilloni, D., Gottardi, E., Messa, F., Fava, M., Scaravaglio, P., Bertini, M., Girotto, M., Marinone, C., Ferrero, D., Gallamini, A., Levis, A., Saglio, G. (2003). Significant Correlation Between the Degree of WT1 Expression and the International Prognostic Scoring System Score in Patients With Myelodysplastic Syndromes. JCO 21: 1988-1995 [Abstract] [Full Text]  
• Blue, J. T. (2003). Myelodysplasia: Differentiating Neoplastic from Nonneoplastic Syndromes of Ineffective Hematopoiesis in Dogs. Toxicol Pathol 31: 44-48 [Abstract]  
• Fouillard, L., Labopin, M., Gorin, N.-C., Polge, E., Prentice, H. G., Meloni, G., Reiffers, J., Pigneux, A., Willemze, R., Schattenberg, A., Sica, S., Lagrange, M., Fenneteau, O., Perot, C., Frassoni, F. (2002). Hematopoietic stem cell transplantation for de novo erythroleukemia: a study of the European Group for Blood and Marrow Transplantation (EBMT). Blood 100: 3135-3140 [Abstract] [Full Text]  
• Albitar, M., Manshouri, T., Shen, Y., Liu, D., Beran, M., Kantarjian, H. M., Rogers, A., Jilani, I., Lin, C. W., Pierce, S., Freireich, E. J., Estey, E. H. (2002). Myelodysplastic syndrome is not merely "preleukemia". Blood 100: 791-798 [Abstract] [Full Text]  
• Bass, A. J., Gockerman, J. P., Hammett, E., DeCastro, C. M., Adams, D. J., Rosner, G. L., Payne, N., Davis, P., Foster, T., Moore, J. O., Rizzieri, D. A. (2002). Phase I Evaluation of Prolonged-Infusion Gemcitabine With Irinotecan for Relapsed or Refractory Leukemia or Lymphoma. JCO 20: 2995-3000 [Abstract] [Full Text]  
• Nilsson, L., Astrand-Grundstrom, I., Anderson, K., Arvidsson, I., Hokland, P., Bryder, D., Kjeldsen, L., Johansson, B., Hellstrom-Lindberg, E., Hast, R., Jacobsen, S. E. W. (2002). Involvement and functional impairment of the CD34+CD38-Thy-1+ hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 100: 259-267 [Abstract] [Full Text]  
• Guardiola, P., Runde, V., Bacigalupo, A., Ruutu, T., Locatelli, F., Boogaerts, M. A., Pagliuca, A., Cornelissen, J. J., Schouten, H. C., Carreras, E., Finke, J., van Biezen, A., Brand, R., Niederwieser, D., Gluckman, E., de Witte, T. M. (2002). Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 99: 4370-4378 [Abstract] [Full Text]  
• Bunworasate, U., Arnouk, H., Minderman, H., O'Loughlin, K. L., Sait, S. N. J., Barcos, M., Stewart, C. C., Baer, M. R. (2001). Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia. Blood 98: 3492-3494 [Abstract] [Full Text]  
• Zang, D. Y., Goodwin, R. G., Loken, M. R., Bryant, E., Deeg, H. J. (2001). Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood 98: 3058-3065 [Abstract] [Full Text]  
• Kurzrock, R., Cortes, J., Thomas, D. A., Jeha, S., Pilat, S., Talpaz, M. (2001). Pilot Study of Low-Dose Interleukin-11 in Patients With Bone Marrow Failure. JCO 19: 4165-4172 [Abstract] [Full Text]  
• Teofili, L., Martini, M., Di Mario, A., Rutella, S., Urbano, R., Luongo, M., Leone, G., Larocca, L. M. (2001). Expression of p15ink4b gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors. Blood 98: 495-497 [Abstract] [Full Text]  
• Harris, E. S., Shigeoka, A. O., Li, W., Adams, R. H., Prescott, S. M., McIntyre, T. M., Zimmerman, G. A., Lorant, D. E. (2001). A novel syndrome of variant leukocyte adhesion deficiency involving defects in adhesion mediated by {beta}1 and {beta}2 integrins. Blood 97: 767-776 [Abstract] [Full Text]  
• Birnbaum, A. J., Gentile, P. (2000). Treatment of Myelodysplasia in a Patient with Active Rheumatoid Arthritis. ANN INTERN MED 133: 753-754 [Full Text]  
• Nilsson, L., Astrand-Grundstrom, I., Arvidsson, I., Jacobsson, B., Hellstrom-Lindberg, E., Hast, R., Jacobsen, S. E. W. (2000). Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 96: 2012-2021 [Abstract] [Full Text]  
• Hamidou, M. A., Derenne, S., Audrain, M. A. P., Berthelot, J. M., Boumalassa, A., Grolleau, J. Y. (2000). Prevalence of rheumatic manifestations and antineutrophil cytoplasmic antibodies in haematological malignancies. A prospective study. Rheumatology (Oxford) 39: 417-420 [Abstract] [Full Text]  
• Hellstrom-Lindberg, E., Willman, C., Barrett, A. J., Saunthararajah, Y. (2000). Achievements in Understanding and Treatment of Myelodysplastic Syndromes. ASH Education Book 2000: 110-132 [Abstract] [Full Text]